Yang Yingying - Shandong Provincial Key Laboratory of Small Molecular Targeted Drugs, Qilu Pharmaceutical Co, Ltd

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Yuanyuan Zhao,Yuxiang Ma,Aimin Zang,Ying Cheng,Yiping Zhang,Xiangcai Wang,Zhendong Chen,Song Qu,Jianbo He,Chuanben Chen,Chuan Jin,Dongyuan Zhu,Qingshan Li,Xianling Liu,Wuyun Su,Yi Ba,Yanrong Hao, Junmin Chen, Guoping Zhang,Shenhong Qu,Yong Li,Weineng Feng,Mengxiang Yang,Baorui Liu,Weiwei Ouyang,Jin Liang,Zhuang Yu,Xiaoyan Kang,Shilin Xue, Guihong Yang,Wei Yan,Yingying Yang, Zhi Liu,Yufeng Peng,Bill Fanslow, Xian Huang,Li Zhang,Hongyun Zhao

Journal of Hematology & Oncologyno. 1 (2023): 1-16

引用3浏览0WOS引用

Iruplinalkib (WX‑0593), a Novel ALK/ROS1 Inhibitor, Overcomes Crizotinib Resistance in Preclinical Models for Non-Small Cell Lung Cancer

Yingying Yang,Qingmei Zheng,Xinmei Wang,Shuyong Zhao, Wenshu Huang,Linchao Jia,Cuicui Ma, Shicong Liu, Yongpeng Zhang, Qianqian Xin, Yan Sun,Shansong Zheng

Investigational new drugs（2023）

引用4浏览0WOS引用

Standard: Human Intestinal Organoids

Cell Regenerationno. 1 (2023): 1-5

引用1浏览0引用

Abstract 5457: QLH11811, a Selective 4Th-Generation EGFR Inhibitor for Osimertinib-Resistant EGFR-mutant NSCLC

Shansong Zheng, Wei Deng,Qingmei Zheng,Yingying Yang, Na Li, Tan Pang, Xueying Feng,Simon Taylor, Lina Ma, Yaqiong Wu, Ziwei Zhao

Cancer researchno. 12_Supplement (2022): 5457-5457

引用0浏览0引用

QLH11811, a selective 4^th-generation EGFR inhibitor for osimertinib-resistant EGFR-mutant NSCLC

Shansong Zheng, Wei Deng,Qingmei Zheng,Yingying Yang, Na Li, Tan Pang, Xueying Feng,Simon Taylor, Lina Ma, Yaqiong Wu, Ziwei Zhao

CANCER RESEARCHno. 12 (2022)

引用0浏览0引用

WX-0593 Combined with an Epithelial Growth Factor Receptor (EGFR) Monoclonal Antibody in the Treatment of Xenograft Tumors Carrying Triple EGFR Mutations

Qingmei Zheng, Dongmei Chen,Xinmei Wang,Yingying Yang,Shuyong Zhao,Xin Dong,Cuicui Ma,Xin Zhang,Huicheng Duan, Yan Sun,Shansong Zheng

Annals of Translational Medicine（2022）

引用2浏览0WOS引用

Abstract 4794: Preclinical Evaluation of WX-0593, a Potent Orally Active ALK Inhibitor

Liu Xile,Charles Z. Ding,Weifeng Mao,Yuxin Qin,Shansong Zheng,Yingying Yang,Qingmei Zheng,Long Zhang,Shuyong Zhao

CANCER RESEARCH（2018）

引用1浏览0引用

Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors

Long Zhang,Yingying Yang,Haojie Zhou,Qingmei Zheng,Yuhao Li,Shansong Zheng,Shuyong Zhao, Dong Chen,Chuanwen Fan

European Journal of Medicinal Chemistry（2015）

引用26浏览0WOS引用

Synthesis and in Vivo Sar Study of Indolin-2-One-Based Multi-Targeted Inhibitors As Potential Anticancer Agents

Long Zhang,Qingmei Zheng,Yingying Yang,Haojie Zhou,Xingjiang Gong,Shuyong Zhao,Chuanwen Fan

European journal of medicinal chemistry（2014）

引用29浏览0WOS引用

Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer

Long Zhang,Chuanwen Fan,Zongru Guo,Ying Li,Shuyong Zhao,Shaobo Yang,Yingying Yang,Jianrong Zhu,Dong Lin

European Journal of Medicinal Chemistry（2013）

引用23浏览0WOSSCOPUS引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn